文献速递慢阻肺

ERS声明:COPD急性加重管理临床试验的核心结局集

ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.
PubMed 文献 · Eur Respir J · 2022-05-05

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients.…

要点

  • 共识基于86例患者访谈和1063名参与者两轮Delphi调查。
  • 建议对部分测量工具开展方法学研究以验证和优化。

研究设计与样本

  • 通过方法学系统综述和11国86例患者定性访谈识别结局,经88国1063名参与者两轮Delphi调查及两次全球共识会议制定核心结局集。

主要发现

  • 核心结局集包括生存、治疗成功、呼吸困难、生活质量、日常生活活动、需要更高水平照护、动脉血气、疾病进展、未来急性加重和住院、治疗安全性和依从性。
  • 建议开展聚焦方法学研究以进一步验证和优化部分所选测量工具。
  • 专家组认为优先结局集及相关测量工具对患者和医护人员不构成负担。

关键数值与推荐

  • 核心结局集包含生存、治疗成功、呼吸困难、生活质量、日常生活活动、需要更高水平照护、动脉血气、疾病进展、未来急性加重和住院、治疗安全性和依从性。
  • 推荐为每个优先结局选择单一测量工具进行评估。

临床怎么用

  • 未来COPD急性加重管理临床试验应统一评估核心结局集所列结局,并使用优先选择的测量工具。

局限性

  • 部分所选测量工具需进一步方法学研究验证和优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Mathioudakis AG, Abroug F, Agusti A, et al. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Respir J. 2022. PMID: 34649975. doi:10.1183/13993003.02006-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。